NEXI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NEXI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
NexImmune's other current assets for the quarter that ended in Jun. 2024 was $0.70 Mil.
NexImmune's quarterly other current assets increased from Dec. 2023 ($0.76 Mil) to Mar. 2024 ($1.59 Mil) but then declined from Mar. 2024 ($1.59 Mil) to Jun. 2024 ($0.70Mil).
NexImmune's annual other current assets declined from Dec. 2021 ($4.46 Mil) to Dec. 2022 ($2.65 Mil) declined from Dec. 2022 ($2.65 Mil) to Dec. 2023 ($0.76 Mil).
The historical data trend for NexImmune's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexImmune Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Other Current Assets | Get a 7-Day Free Trial | 0.90 | 3.36 | 4.46 | 2.65 | 0.76 |
NexImmune Quarterly Data | ||||||||||||||||||||
Dec18 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Other Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2.15 | 1.28 | 0.76 | 1.59 | 0.70 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of NexImmune's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Alan S. Roemer | director | C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018 |
Timothy Stover | officer: VP, Corporate Controller | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
Sol J Barer | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Zhengbin Yao | director | 10301 STELLA LINK ROAD, HOUSTON TX 77025 |
Leena Gandhi | director | C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878 |
Timothy Bertram | director | C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403 |
Paul D'angio | director | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
Grant Verstandig | director | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
Mathias Oelke | officer: Chief Science Officer | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878 |
Kristi Jones | officer: Chief Operating Officer | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
Jerome B Zeldis | officer: EVP of R&D | 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
Scott Carmer | director, officer: President and CEO | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
John Trainer | officer: Chief Financial Officer | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
Robert Douglas Knight | officer: Chief Medical Officer | C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877 |
From GuruFocus
By GuruFocus Research • 02-08-2024
By Marketwired • 08-31-2023
By Marketwired • 08-10-2023
By Marketwired • 10-18-2023
By sperokesalga sperokesalga • 05-15-2023
By sperokesalga sperokesalga • 05-22-2023
By sperokesalga sperokesalga • 03-28-2023
By sperokesalga sperokesalga • 02-16-2023
By GuruFocusNews GuruFocusNews • 06-19-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.